In phase-I trial, involving 31 patients with refractory HER2-positive breast cancer, infusion with expanded activated autologous NK cells enhanced trastuzumab-mediated ADCC and produced a potent killing effect on breast cancer (8). The gene discussed is ERBB2; the disease is breast cancer.